References
  1. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270–3.
  2. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel corona virüs from patients with pneumonia in China, 2019. N Engl. J. Med. 2020;382(8):727–33.
  3. Zhang JJ, Dong X, Cao YY, Yuan YD, Yang YB, Yan YQ. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy. 2020.
  4. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel corona virüs pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507–13.
  5. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan. China. Lancet. 2020;395(10223):497–506.
  6. Xiong Y, Liu Y, CaoL, Wang D, Guo M, Jiang A, et al. Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients. Emerg Microbes Infect. 2020;9(1):761–70.
  7. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061.
  8. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poorprognosis in patients with novel corona virüs pneumonia. J. Thromb. Haemost. 2020;18(4):844–7.
  9. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors formortality of adult in patients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–62.
  10. Luo W, YuH,Guo Z, Li X, Sun Y, Li J, et al. Clinical pathology of critical patient with novel corona virüs pneumonia (COVID-19). Preprints. 2020.www.preprints.org.
  11. Ding Y, Wang H, Shen H, Li Z, Geng J, Han H et al. The clinical pathology of severe acute respiratory syndrome (SARS): a report from China. J. Pathol. 2003;200(3):282–9.
  12. Klok FA, Kruip M, van der Meer NJM, Arbous MS, Gommers D, Kant KM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb. Res. 2020. doi.10.1016/j. thromres. 2020.04.013.
  13. Cui S, Chen S, Li X, Liu S, Wang F. Prevalence of venous thromboembolism in patients with severe novel corona virüs pneumonia. J.Thromb. Haemost. 2020
  14. Xiong M, LiangX, Wei YD. Changes in blood coagulation in patients with severe corona virüs disease 2019 (COVID-19): a meta-analysis. British Society for Haematology and John Wiley&Sons Ltd. 2020.
  15. Connors JM, Levy JH. COVID-19 and it simplications for thrombosis and anticoagulation. Blood. 2020.
  16. Bikdeli B, Madhavan MV, Jimenez D, Chuich T, Dreyfus I, Driggin E et al. COVID-19 and thromboticor thromboembolic disease: Implications for prevention, anti thrombotic therapy, andfollow-up. J. Am. Coll. Cardiol. 2020;(4):0735-1097(20)35008-7.
  17. Zhang L, Yan X, Fan Q, Liu H, Liu X, Liu Z, Zhang Z. D-dimer levels on admission to predict in hospital mortality in patients with Covid-19. J. Thromb. Haemost. 2020;18(6):1324-1329.
  18. Lippi G, Plebani M, Henry BM. Thrombocytopenia is associated with severe corona virüs disease 2019 (COVID-19) infections: a meta-analysis. Clin. Chim. Acta. 2020;506:145-148.
  19. Khurana D, Deoke SA. Thrombocytopenia in critically ill patients: clinical and laboratorial behavior and its correlation with short- term outcome during hospitalization. Indian J. Crit. Care Med. 2017;21(12):861–864.
  20. Yang X, Yang Q, Wang Y, Wu Y, Xu J, Yu Y, et al. Thrombocytopenia and its association with mortality in patients with COVID-19. J Thromb Haemost. 2020;18:1469–72.
  21. Yang Z, Shi J, He Z, et al. Predictors for imaging progression on chest CT from corona virüs disease 2019 (COVID-19) patients. Aging. 2020;12:6037–6048.
  22. Ganji A, Farahani I, Khansarinejad B, et al. Increased expression of CD(8) marker on T-cells in COVID-19 patients. Blood Cells Mol. Dis. 2020;83:102437.
  23. Tang N, Bai H, Chen X, et al. Anticoagulant treatment is associated with decreased mortality in severe corona virus disease 2019 patients with coagulopathy. J. Thromb. Haemost. 2020;18(5):1094–1099.
  24. Wakai A, Gleeson A, Winter D. Role of fibrin D-dimertesting in emergency medicine. Emergency Medicine Journal. 2003; 20: 319-325.
  25. Hayakawa M, Maekawa K, Kushimoto S, et al. High D-dimer levels predict a pooroutcome in patients with severe trauma, even with high fibrinogen levels on arrival: a multi center retrospective study. Shock 2016; 45(3): 308–314.
  26. Schutte T, Thijs A, Smulders YM. Never ignore extremely elevated D-dimer levels: they are specific for serious illness. The Netherlands Journal of Medicine 2016; 74(10): 443–448.
  27. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of corona virüs disease 2019 in China. N. Engl. J. Med. 2020;382:1708–20.
  28. Petrilli CM, Jones SA, Yang J, Rajagopalan H, O’Donnel L, Chernyak Y, et al. Factors associated with hospital admission and critical illness among 5279 people with corona virüs disease 2019 in New York City: prospective cohort study. BMJ. 2020;369: m1966.
  29. Guo T, Fan Y, Chen M, Wu X, Zhang L, He T, Wang H, Wan J, Wang X, Lu Z. Cardiovascular implications of fatal outcomes of patients with corona virüs disease 2019 (COVID-19). JAMA Cardiology. 2019.